Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental cell therapy targets tough lung cancers

NCT ID NCT05676749

First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 24 times

Summary

This early-phase study tested a personalized cell therapy (C-TIL051) for people with advanced non-small cell lung cancer that no longer responded to standard anti-PD1 drugs. Participants provided a tumor sample to grow immune cells, then received chemotherapy followed by an infusion of those cells plus additional immune-boosting drugs. The goal was to check safety and see if the cancer would shrink. Only one person enrolled before the study was stopped.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Allegheny Health Network-West Penn Hospital

    Pittsburgh, Pennsylvania, 15224, United States

  • Duke Center for Cancer Immunotherapy

    Raleigh, North Carolina, 27710, United States

  • Ochsner MD Anderson Cancer Center

    New Orleans, Louisiana, 70121, United States

Conditions

Explore the condition pages connected to this study.